GlassScriptPhysician profile
Roy Allen Williams
NPI 1063428076
$2,268.73
in general payments reported to CMS, 2019-2025
25 companies · $32.51 in 2025
The $32.51 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $328 · 2022: $212 · 2023: $192 · 2024: $162 · 2025: $32.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $598.46 | 2022-2025 | Atricure Cryoice Cryoablation System (Cryo2), Synergy Ablation System, Atriclip Laa Exclusion System |
| E.R. Squibb & Sons, L.L.C. | $470.47 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $158.33 | 2019-2020 | |
| Janssen Biotech, INC. | $100.52 | 2019 | |
| Celgene Corporation | $93.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $92.57 | 2019-2020 | |
| Daiichi Sankyo INC. | $82.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $80.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.60 | 2019-2020 | |
| Incyte Corporation | $60.57 | 2019-2020 | |
| Emd Serono, INC. | $52.14 | 2019-2020 | |
| Eisai INC. | $51.12 | 2019-2020 | |
| Taiho Oncology, INC. | $50.28 | 2019 | |
| Genentech USA, INC. | $47.20 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $38.58 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $34.16 | 2019 | |
| Seagen INC. | $33.25 | 2019-2020 | |
| Csl Behring | $32.06 | 2019-2020 | |
| Genzyme Corporation | $26.71 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $25.17 | 2019-2020 | |
| Astellas Pharma US INC | $19.05 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.46 | 2019 | |
| Pfizer INC. | $17.00 | 2019 | |
| Lilly USA, LLC | $12.50 | 2019 | |
| Amgen INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.